Sapient Capital LLC Buys 3,404 Shares of AbbVie Inc. (NYSE:ABBV)

Sapient Capital LLC lifted its position in AbbVie Inc. (NYSE:ABBV) by 1.3% during the 4th quarter, according to the company in its most recent filing with the SEC. The fund owned 258,899 shares of the company’s stock after purchasing an additional 3,404 shares during the quarter. AbbVie accounts for approximately 0.9% of Sapient Capital LLC’s holdings, making the stock its 22nd biggest holding. Sapient Capital LLC’s holdings in AbbVie were worth $46,006,000 at the end of the most recent reporting period.

A number of other hedge funds have also made changes to their positions in the company. Pineridge Advisors LLC grew its stake in AbbVie by 8.4% during the fourth quarter. Pineridge Advisors LLC now owns 1,020 shares of the company’s stock worth $181,000 after buying an additional 79 shares during the last quarter. Principle Wealth Partners LLC boosted its holdings in shares of AbbVie by 0.3% in the 4th quarter. Principle Wealth Partners LLC now owns 33,751 shares of the company’s stock worth $5,998,000 after acquiring an additional 105 shares in the last quarter. International Private Wealth Advisors LLC bought a new stake in AbbVie during the 4th quarter worth approximately $644,000. Arlington Trust Co LLC increased its holdings in AbbVie by 1.5% during the 4th quarter. Arlington Trust Co LLC now owns 6,778 shares of the company’s stock valued at $1,204,000 after purchasing an additional 100 shares in the last quarter. Finally, Equitable Trust Co. raised its position in AbbVie by 1.7% in the 4th quarter. Equitable Trust Co. now owns 34,823 shares of the company’s stock valued at $6,188,000 after purchasing an additional 597 shares during the last quarter. Institutional investors and hedge funds own 70.23% of the company’s stock.

AbbVie Stock Down 0.2 %

AbbVie stock opened at $190.31 on Tuesday. AbbVie Inc. has a fifty-two week low of $153.58 and a fifty-two week high of $207.32. The company has a debt-to-equity ratio of 9.64, a current ratio of 0.65 and a quick ratio of 0.54. The firm has a market capitalization of $336.30 billion, a price-to-earnings ratio of 79.29, a PEG ratio of 1.53 and a beta of 0.58. The company’s 50 day simple moving average is $177.54 and its 200 day simple moving average is $185.75.

AbbVie (NYSE:ABBV) last announced its quarterly earnings results on Friday, January 31st. The company reported $2.16 earnings per share (EPS) for the quarter, missing the consensus estimate of $2.98 by ($0.82). AbbVie had a net margin of 7.59% and a return on equity of 257.91%. During the same quarter last year, the business posted $2.79 earnings per share. As a group, sell-side analysts anticipate that AbbVie Inc. will post 12.32 EPS for the current year.

Wall Street Analysts Forecast Growth

Several analysts have recently commented on the company. Daiwa Capital Markets cut AbbVie from an “outperform” rating to a “neutral” rating and set a $180.00 target price on the stock. in a report on Thursday, December 5th. Sanford C. Bernstein began coverage on shares of AbbVie in a research report on Thursday, October 17th. They issued a “market perform” rating and a $203.00 price objective for the company. Leerink Partners raised shares of AbbVie from a “market perform” rating to an “outperform” rating and set a $206.00 target price for the company in a research note on Friday, November 22nd. Daiwa America cut shares of AbbVie from a “strong-buy” rating to a “hold” rating in a research note on Thursday, December 5th. Finally, Guggenheim boosted their price objective on shares of AbbVie from $212.00 to $214.00 and gave the stock a “buy” rating in a research report on Monday, February 3rd. Five analysts have rated the stock with a hold rating, seventeen have given a buy rating and two have given a strong buy rating to the company’s stock. According to MarketBeat.com, the company currently has an average rating of “Moderate Buy” and a consensus target price of $208.35.

Insiders Place Their Bets

In other news, SVP Kevin K. Buckbee sold 1,800 shares of AbbVie stock in a transaction dated Monday, December 16th. The stock was sold at an average price of $172.24, for a total transaction of $310,032.00. Following the transaction, the senior vice president now owns 6,983 shares in the company, valued at $1,202,751.92. The trade was a 20.49 % decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available at this hyperlink. Corporate insiders own 0.25% of the company’s stock.

AbbVie Company Profile

AbbVie Inc discovers, develops, manufactures, and sells pharmaceuticals worldwide. The company offers Humira, an injection for autoimmune and intestinal Behçet's diseases, and pyoderma gangrenosum; Skyrizi to treat moderate to severe plaque psoriasis, psoriatic disease, and Crohn's disease; Rinvoq to treat rheumatoid and psoriatic arthritis, ankylosing spondylitis, atopic dermatitis, axial spondyloarthropathy, ulcerative colitis, and Crohn's disease; Imbruvica for the treatment of adult patients with blood cancers; Epkinly to treat lymphoma; Elahere to treat cancer; and Venclexta/Venclyxto to treat blood cancers.